LOS ANGELES, March 21, 2022 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming April 1, 2022 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ: STTK) securities: (1) pursuant and/or traceable to the registration statement and related prospectus (collectively, the “Registration Statement”) issued in connection with Shattuck’s October 2020 initial public offering (the “IPO” or “Offering”); and/or (2) between October 9, 2020 and November 9, 2021, inclusive (the “Class Period”). Shattuck investors have until April 1, 2022 to file a lead plaintiff motion.
If you suffered a loss on your Shattuck investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at www.glancylaw.com/cases/shattuck-labs-inc/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at shareholders@glancylaw.com to learn more about your rights.
On or about October 9, 2021, Shattuck conducted its IPO, selling approximately 13.7 million shares at $17.00 per share.
On November 9, 2021, Shattuck announced that it had terminated its Collaboration Agreement with Millennium Pharmaceuticals, Inc. (“Takeda”), a wholly owned subsidiary of Takeda Pharmaceutical Company, Ltd. The Company issued a press release stating that “Shattuck and Takeda mutually agreed” to the termination and that “the Company will not make any payments to or receive any future milestone or royalty payments from Takeda.”
On this news, Shattuck’s stock fell $5.45, or 28%, to close at $13.59 per share on November 9, 2021, thereby injuring investors. On January 28, 2022, the Company’s share price closed at $6.13 per share, less than half of its original IPO price.
The complaint alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose: (1) the Collaboration Agreement with Takeda was not solid; (2) Takeda and Shattuck would mutually agree to terminate the Collaboration Agreement in essentially one year; (3) as a result, Shattuck would cease to receive any future milestone, royalty, or other payments from Takeda; and (4) as a result, defendants statements about the Company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
Follow us for updates on LinkedIn, Twitter, or Facebook.
If you purchased or otherwise acquired Shattuck securities during the Class Period, you may move the Court no later than April 1, 2022 to request appointment as lead plaintiff in this putative class action lawsuit. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact Charles Linehan, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contacts
Glancy Prongay & Murray LLP, Los Angeles
Charles Linehan, 310-201-9150 or 888-773-9224
shareholders@glancylaw.com
www.glancylaw.com
